跳至主要内容
临床试验/JPRN-UMIN000025278
JPRN-UMIN000025278已完成未知

An observational study of EGFR mutation status by circulating tumor DNA during the osimertinib treatment of lung cancer harboring EGFR activating and T790M mutations. - An observational study of plasma EGFR mutation status during osimertinib treatment.

Miyagi Cancer Center0 个研究点目标入组 60 人开始时间: 2016年12月20日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Having an evidence of ILD or pulmonary fibrosis complication on chest X-ray. 2. Having a history or serious complications as bellows: 1) uncontrollable angina pectoris, cardial infarction within 3 months before enrollment, or heart failure. 2) uncontrollable diabetes or hypertension. 3) Severe infectious disease.. 4) gastrointestinal dysfunction with severe diarrhea. 3. Impossible to take drugs orally. 4. Inadequate case considered from drug package insert of osimertinib.

研究者

相似试验